The antiatherogenic dose response effect of verapamil in an experimental atherosclerosis model in the rabbit
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
1842941
Knihovny.cz E-zdroje
- MeSH
- aorta thoracica patologie MeSH
- arterioskleróza patologie MeSH
- beta-galaktosidasa krev MeSH
- cholesterol dietní aplikace a dávkování MeSH
- cholesterol krev MeSH
- dipeptidylpeptidasy a tripeptidylpeptidasy krev MeSH
- esterasy krev MeSH
- glukosa-6-fosfátdehydrogenasa krev MeSH
- králíci MeSH
- krevní tlak fyziologie MeSH
- kyselá fosfatasa krev MeSH
- svaly hladké cévní patologie MeSH
- triglyceridy krev MeSH
- verapamil farmakologie MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- beta-galaktosidasa MeSH
- cholesterol dietní MeSH
- cholesterol MeSH
- dipeptidylpeptidasy a tripeptidylpeptidasy MeSH
- esterasy MeSH
- glukosa-6-fosfátdehydrogenasa MeSH
- kyselá fosfatasa MeSH
- triglyceridy MeSH
- verapamil MeSH
The aim of the study was to assess the dose dependence of the antiatherogenic effect of verapamil (Isoptin, Lek Ljubljana, Yugoslavia) in rabbits fed 1% cholesterol diet. Verapamil was administered subcutaneously at doses of 0.25, 1 and 2 mg.kg-1/day at 12-hour intervals for 8 weeks. The results indicate verapamil administered s.c. exerts a preventive anti-atherosclerotic effect only in therapeutic doses (0.25 mg.kg-1). The beneficial effect of low-dose verapamil can also be seen in the spectrum of serum lipids as the drug lowers the levels of total cholesterol and triacylglycerols. Compared with the results obtained from a group receiving diet without Ca-antagonist premedication, high doses do not reduce the extent of atheromatous plaques.